ArticleNature communications2022
Identifying regions for enhanced control of gambiense sleeping sickness in the Democratic Republic of Congo.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Understanding Nash epidemics.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Comparison of stochastic and deterministic models for gambiense sleeping sickness at different spatial scales: A health area analysis in the DRC.PLoS computational biology · 2024Article
- Modelling morbidity for neglected tropical diseases: the long and winding road from cumulative exposure to long-term pathology.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- Rational social distancing policy during epidemics with limited healthcare capacity.PLoS computational biology · 2023Article
- Health economic evaluation of strategies to eliminate gambiense human African trypanosomiasis in the Mandoul disease focus of Chad.PLoS neglected tropical diseases · 2023Article
- A modelling assessment of short- and medium-term risks of programme interruptions for gambiense human African trypanosomiasis in the DRC.PLoS neglected tropical diseases · 2023Article
- Article
- Article
- Modelling to infer the role of animals in gambiense human African trypanosomiasis transmission and elimination in the DRC.PLoS neglected tropical diseases · 2022Article
- Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo.Nature communications · 2022Article
- Economic evaluation of disease elimination: An extension to the net-benefit framework and application to human African trypanosomiasis.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- How modelling can help steer the course set by the World Health Organization 2021-2030 roadmap on neglected tropical diseases.Gates open research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gambiense human African trypanosomiasis (sleeping sickness, gHAT) is a disease targeted for elimination of transmission by 2030. While annual new cases are at a historical minimum, the likelihood of achieving the target is unknown. We utilised modelling to study the impacts of four strategies using currently available interventions, including active and passive screening and vector control, on disease burden and transmission across 168 endemic health zones in the Democratic Republic of the Congo. Median projected years of elimination of transmission show only 98 health zones are on track despite significant reduction in disease burden under medical-only strategies (64 health zones if > 90% certainty required). Blanket coverage with vector control is impractical, but is predicted to reach the target in all heath zones. Utilising projected disease burden under the uniform medical-only strategy, we provide a priority list of health zones for consideration for supplementary vector control alongside medical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.